Two multicenter trials drew different conclusions about the value of conduction system relative to biventricular pacing for left bundle branch block in heart failure.
Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE Study March 23, 2026 4:30 ...
With me on today's call are Relmada Therapeutics, Inc.'s CEO, Dr. Sergio Traversa, who will briefly provide a summary of ...
Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, ...
As a potential biomarker of treatment response, ctDNA and utDNA analyses were performed before systemic therapy, at restaging, and for responders at the beginning of adjuvant nivolumab. ctDNA was ...
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2025 Earnings Call Transcript March 19, 2026 Relmada Therapeutics, Inc. misses on ...
A growing body of research seeks to validate ctDNA as a means of guiding MIBC treatment, particularly immunotherapy.
Newspoint on MSN
Transformative trends in life sciences: The future of pharmaceuticals and biotechnology
Current Landscape of Life Sciences The life sciences sector, encompassing pharmaceuticals, biotechnology, and medical devices ...
Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, including first evidence of activity in gastric cancer ...
Many hospitalized adults could benefit from linkage to dental care. This article describes a planned study to refer ...
Led by researchers at NDORMS as part of the Data Analysis and Real World Interrogation Network (DARWIN EU) initiative, a new ...
Forty-three current and former C.D.C. employees on the changes they say are replacing science with ideology — and making ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results